The Role of Biomarkers In Medicine

In medicine, a biomarker is a calculable sign of the severity or presence of some disease state. Further mostly, a biomarker is anything that can be used as a sign of a particular disease state or some other physiological state of an organism.

A biomarker is a measurable indicator of some biological condition or condition. The biomarker can be measured objectively and consistently. Biomarkers play an important role in clinical medicine today. The biomarker allows doctors to detect diseases, predict their course and the effectiveness of treatment. An example of a biomarker commonly used in medicine is prostate-specific antigen (PSA). The search for more profitable and measurable biomarkers continues to drive the pharmaceutical industry. The more biomarkers doctors have in their toolbox, the closer we get to precision medicine.

The use of biomarkers in basic and clinical research has become a routine in many areas of medicine. They are established as molecular signatures that have been well considered and have repeatedly been shown to be capable of predicting relevant disease states or clinical outcomes. In the role of biomarkers in medicine, expert researchers in their individual field have reviewed many biomarkers or potential biomarkers in various types of diseases.

The topics discourse many aspects of medicine, representative the current conceptual status of biomarkers as clinical tools and as substitute endpoints in clinical research. 

Biomarkers are used to

•          Predict the response to a treatment
•          Determine treatment efficacy
•          Confirm the stage of a disease
•          Monitor Progression/recurrence
•          Monitor treatment compliance

Biomarkers can be classified into 3 types

•          Natural History markers
•          Drug activity biomarkers
•          Surrogate Markers

It’s our honor and privilege to invite you to participate at International Conference on Biomarkers and Clinical Research going to be held at Abu Dhabi, UAE during July 15-16, 2019. I hope you can join us for this event. If you are unable to attend, I encourage you to appoint someone as your proxy, colleagues and students to attend the event on your behalf

Biomarkers to detect and prevent liver cancer

Liver cancer is a category of cancer that starts in the liver. Some cancers grow outside the liver and extend to the area. However, only cancers that surprise in the liver are defined as liver cancer. It is one of the largest organs of the human body. It has a range of purposes, including eliminating toxins from the body, and is essential to survival.

Growth in the expression of sugar-burning ‘glycolytic’ enzymes in precancerous cirrhotic livers has been recognized and could be used as a biomarker

Liver cancer claims more than 700,000 lives each year and is the second leading cause of cancer-related deaths worldwide. Due to the nature of cancer, it is usually detected too late to heal.

The results of a new study show a huge increase in the expression of "glycolytic" enzymes that burn sugar in precancerous cirrhotic livers. This increase has been associated with a significantly increased risk of developing hepatocellular carcinoma (HCC), a major type of liver cancer, and could be used as a biomarker to identify people at risk of malignancy.

"We know that 90 percent of all cases of hepatocellular carcinoma begin with liver cirrhosis,"

"Then, by pointing out when cirrhosis is progressing towards cancer, we could improve early detection and treatment, with surgery, chemotherapy and radiotherapy, but perhaps also with new treatments that reverse the transition."

"We set out to find features of the cirrhotic cells that could predict a cancerous change," said Dr. Papa.

The research team identified that genes related to glycolysis, including hexokinase 2 (HK2), aldolase A (ALDOA) and pyruvate kinase M2 (PKM2), are highly expressed in HCC and cirrhosis compared to normal liver samples.

"In other words: the change to glycolysis occurs in the precancerous stage," said Dr. Bubici. "This suggests that the expression of glycolytic enzymes could be used as a new biomarker to predict the risk of subsequent development of HCC in patients with cirrhosis."

The researchers concluded that the findings reveal a promising means of improving HCC survival through early detection and treatment.

Cordial Consent for your presence at International Conference on Biomarkers and Clinical Research which is going to be held during July 15-16, 2019 Abu Dhabi, UAE

Contact Us

P: +1-201-380-5561
Email: biomarkers@memeetings.com